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Background: Eradication of Pseudomonas aeruginosa in patients with cystic fibrosis (CF) is possible if
initiated early in the course of colonisation. To detect P aeruginosa as early as possible is therefore a major
goal. This study was undertaken to validate a commercialised test for the detection of serum Pseudomonas
antibodies in patients with CF.
Methods: A representative cross sectional analysis of serum antibodies against three Pseudomonas
antigens (alkaline protease, elastase, and exotoxin A) was performed in 183 patients with CF of mean age
16.7 years and FEV1 85.9% predicted. The results were correlated with microbiological results from the
previous 2 years to calculate sensitivity, specificity, positive and negative predictive values. The following
2 years were assessed to determine prognostic predictive values.
Results: A combination of all three tested antibodies yielded the best results with a sensitivity of 86%,
specificity of 96%, and a positive predictive value of 97%. These values were higher if only patients in
whom sputum cultures were available were considered (n = 76, sensitivity 95%, specificity 100%, positive
predictive value 100%). The prognostic positive predictive value was high in intermittently infected patients
(83%) but low in patients free of infection (33%), whereas the prognostic negative predictive value was
high in patients free of infection (78%) and low in intermittently infected patients (58%).
Conclusions: Regular determination of serum antibodies may be useful in CF patients with negative or
intermittent but not with positive P aeruginosa status. A rise in antibody titres indicates probable infection and
eradication treatment may be initiated even in the absence of microbiological detection of P aeruginosa.
C
ystic fibrosis (CF) is the most frequent life threatening
autosomal recessive disorder in white subjects. It is
caused by mutations in the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene, leading to
disturbed ion transport across epithelial cells. The clinical
consequences of this basic defect are seen in exocrine glands,
causing pancreatic insufficiency and progressive pulmonary
insufficiency which is the major cause of morbidity and
mortality in CF patients. The airway epithelium is susceptible
to lower respiratory tract colonisation involving infection and
inflammation, even in patients with clinically mild lung
disease.1 The most frequently reported respiratory pathogen is
Pseudomonas aeruginosa,2 which is cultured in specimens from
up to 21% of CF children under 1 year of age and, in the
absence of a policy of early eradication treatment, increasing
to .80% at 26 years or older.2 3 Identification of mucoid
forms of P aeruginosa is thereby an unfavourable prognostic
factor for survival.4
Eradication of this organism is usually not possible in cases of
chronic colonisation and infection, but there is evidence that
early antibiotic treatment reduces the rate of positive cultures in
CF patients with newly isolated P aeruginosa.5 A major goal is
therefore to detect P aeruginosa as early as possible to use the
window of opportunity for possible eradication.6 From this
point of view, bronchoalveolar lavage or spontaneous or
induced sputum cultures obtained at regular intervals would
be the desirable ‘‘gold standard’’ methods for the microbiolo-
gical detection of P aeruginosa.7 However, in clinical practice we
often have to rely on the results from oropharyngeal swab
cultures because the patients are too young or too healthy to
expectorate, and this method is the only direct and readily non-
invasive technique available to obtain respiratory secretions for
culture.
An alternative approach is to track P aeruginosa colonisation
by testing for serum antibodies against this organism,
especially as they may be detected clearly before the organism
is isolated from respiratory samples.2 8 Since serum precipi-
tins and antibodies against P aeruginosa have been
described2 9–11 and the first ELISA against Pseudomonas
antigens was developed,12 attempts have been made to
correlate the acquisition of P aeruginosa with the production
of an antibody response against this organism.13–19 Reviewing
the published data, a correlation between microbiological
findings, clinical state, and results of antibody determination
is definite for cohorts of CF patients, whereas the impact of
an individual result of serum antibodies against P aeruginosa
remains difficult to interpret.
This study was undertaken to assess the diagnostic
accuracy of a commercial antibody ELISA test in relation to
the microbiological findings from respiratory secretions and
to estimate the prognostic value of these antibody test results
to anticipate the future trend of microbiological results. The
particular test is a further development of a radioimmunoas-
say developed by Do¨ring and Hoiby18 which permits the
determination of three major extracellular proteins of P
aeruginosa—namely, alkaline protease (AP), elastase (E), and
exotoxin A (EA). These proteins show high grade immuno-
genicity and are expressed by nearly all strains of P aeruginosa.
METHODS
Subjects and study design
Routine regular determination of serum antibodies against P
aeruginosa was introduced in our CF centre in 2000. To
conduct a representative cross sectional analysis of P
aeruginosa antibody titres in patients with CF, antibody test
Abbreviations: AP, alkaline protease; CF, cystic fibrosis; E, elastase;
EA, exotoxin A; ELISA, enzyme linked immunoassay; FEV1, forced
expiratory volume in 1 second; NPV, negative predictive value; OD,
optical density; PPV, positive predictive value
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results obtained between 2000 and 2002 were extracted. The
antibody test results were correlated, firstly, with known
microbiological data from the previous 2 years and, secondly,
with microbiological results from the following 2 years.
Of 421 patients with CF attending the Cystic Fibrosis
Centre at the Children’s University Hospital in Munich
between 2000 and 2002 (mean age 16.3 years, median 15.4,
range 0.4–41), 212 patients were seen continuously at three
monthly intervals by one physician of whom 187 agreed to
participate in the study. Three patients were excluded from
the study because, after vaccination against P aeruginosa, they
had known serum antibodies against EA. One patient was
excluded because, after 14 years of chronic P aeruginosa
infection, he underwent lung transplantation 3 years before
the study was started and consequently changed microbio-
logically to not being infected with this organism. The mean
age of the remaining 183 patients was 16.7 years (range
15.7– 24.1), mean forced expiratory volume in 1 second
(FEV1) was 85.9% predicted (median 89; range 20–147),
mean weight for height 105% (median 104; range 62–158).
181 patients (99%) were on continuous (.300 days/year)
oral antibiotic therapy against Staphylococcus aureus. Weight
and height were measured at the beginning of the study and
the weight for height predicted was calculated using height
percentile standards given by Prader et al.20
The patients were divided into three groups according to
the number of positive microbiological cultures of P aeruginosa
in the previous 2 years: free of P aeruginosa (0 positive of 8
cultures); intermittently colonised (1–6 positive of 8 cultures);
and chronically colonised (>7 positive of 8 cultures). The
clinical details of these subjects are shown in table 1 and their
age distribution and P aeruginosa status are given in fig 1.
Complete microbiological data over the following 2 years for
at least seven of eight possible microbiological samples was
available in 162 of the183 patients (overall rate 88.5%, 66/68
patients in the P aeruginosa free group, 24/27 patients in the
intermittently infected group, and 68/88 patients in the
chronically infected group).
Informed consent was obtained from all subjects. The
study was approved by the local institutional review board for
human studies of the University Children’s Hospital, Munich.
Microbiological and serological assays
Sputum samples or deep oropharyngeal swabs were routinely
obtained every 3 months and, after homogenisation, were
cultured on blood agar plates and McConkey agar plates for
at least 72 hours aerobically at 37 C˚ without the use of
additional selective media for P aeruginosa.
Antibody titres against the three purified P aeruginosa
antigens (AP, E, and EA) were determined using a
commercially available ELISA test system (Mediagnost,
Germany) according to the manufacturer’s instructions.
Two replicates were used for each sample. The antibody
titres were expressed in arbitrary units and categorised as 0
(titre negative ,1:500) or 1 (titre positive .1:500). The
calibration curves of the test system were linear for optical
density (OD) values between 0.1 and 1.7, corresponding to
titres of 1:10 to 1:2000. Negative and positive controls were
provided by the manufacturer and consisted of pooled serum
samples from P aeruginosa positive CF patients and from
normal children, respectively. All measurements were con-
ducted in duplicate for each ELISA panel. For determination
of high titres (.2000), dilutions of 1:10 to 1:100 were used.
The cut off, depending on the slope of the calibration curve,
was reached at a mean (SD) OD of 0.35 (0.046) for all three
antibodies.
Intra- and inter-assay variability of serological
assays
The intra-assay variability (correlation between the results of
duplicate measurements) was excellent for the three differ-
ent antibodies with a Spearman coefficient of correlation of
0.988–0.995 (100% correlation is 1.000) and a Bland-Altman
coefficient of repeatability of 0.091–0.096 (100% correlation is
0.000).
The inter-assay variability (correlation between the results
obtained to generate the ELISA calibration curves) was
satisfactory with a relative coefficient of variation of 7.3–20.3
(a coefficient of 0 represents complete concordance and 100
represents no agreement).
Statistical analysis
The sensitivity, specificity, 95% confidence intervals (95% CI),
positive predictive value (PPV), and negative predictive value
Table 1 Clinical data of 183 patients with CF according to their P aeruginosa status
Free
(n = 68)
Intermittent
(n = 27)
Chronic
(n = 88)
Classified according to sputum (n) 11 5 60
Classified according to swab (n) 57 22 28
Age (years)* 11.4 (2–29) 14.5 (2–41) 21.5 (3–38)
Weight for height (%)* 103 (62–130) 107 (88–148) 105 (78–158)
FEV1 (% predicted)* 97 (62–147) 94 (48–143) 75 (21–128)
IgG (mg/dl)* 842 (294–1962) 966 (296–2440) 1293 (654–2575)
C-reactive protein (mg/dl)* 0.18 (0.00–1.36) 0.14 (0.01–0.58) 0.64 (0.00–3.90)
Detection of mucoid strains (n/N) 0/68 15/27 84/88
*Data expressed as mean (range).
Duration of infection for median of 11.5 years (range 1.5–26).
There were significant differences between the groups in FEV1 depending on age (p = 0.025) but not group
membership (p = 0.35, two way ANOVA).
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Figure 1 Age distribution of 183 patients with CF divided into three
groups according to their microbiological P aeruginosa status: free of P
aeruginosa (0 positive of 8 cultures); intermittently colonised (1–6
positive of 8 cultures); and chronically colonised (>7 positive of 8
cultures).
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(NPV) were calculated from contingency tables with con-
fidence intervals calculated using the binominal exact
method.
To briefly review the concept of diagnostic accuracy with
respect to serum antibodies against P aeruginosa, sensitivity is
the probability that a patient who is colonised with P
aeruginosa shows detectable antibodies against this organism,
and specificity is the probability that a patient who is not
colonised with P aeruginosa shows no detectable antibodies
against this organism. The sensitivity and specificity are
properties of the test and are not determined by the
prevalence of P aeruginosa colonisation in the population
studied. Therefore, neither the sensitivity nor the specificity
answer the most important questions—namely, if the anti-
body result is positive, what is the chance that the patient is
really colonised with P aeruginosa, and if the antibody result is
negative, what is the chance that the patient is not colonised
with this organism? The answers to these questions are given
by the predictive values which take into account the
prevalence: the PPV is the probability that a subject with
positive antibodies against P aeruginosa is colonised with that
organism; the NPV is the probability that a subject with a
negative antibody result is not colonised with P aeruginosa.
In this study we calculated the predictive values account-
ing for the P aeruginosa prevalence retrospectively determined
in our study population according to microbiological results.
Furthermore, we calculated the prospective predictive values
using the antibody test results and the microbiological results
of the following 2 years. The later values state the probability
for a single CF patient to shift his or her P aeruginosa status
dependent on his or her initial antibody titre.
For comparison of paired data, the Spearman coefficient of
correlation and the relative coefficient of variation were
calculated and the coefficient of repeatability was calculated
according to the method proposed by Bland and Altman.21
The Mann-Whitney test was used for comparison of
unrelated data and Fisher’s exact test was used for
categorical variables, corrected for multiple comparisons by
the Bonferroni method. Analyses were performed using SPSS
version 12.0 for Windows (SPSS Inc, Chicago, IL, USA). Data
are given as mean (median, range).
RESULTS
Serum antibodies against P aeruginosa and
correlation with P aeruginosa status defined
retrospectively
The levels and positivity of the three antibodies (AP, E, and
EA) differed substantially between the three groups of CF
patients (table 1). A negative single test was scored as 0 and a
positive test as 1, thus giving a cumulative score (AP or E or
EA) from 0 to a maximum of 3. The patients free of infection,
as determined by culture results from the previous 2 years,
had positive antibody results in only a very small fraction (3/
68 patients) and the mean cumulative score was low (0.06).
The patients with chronic infection had a very high rate of
positive antibody results (86/88 patients) and the mean
cumulative score was high (2.22). The patients with
intermittent infection were in between (13/27 patients
positive) with a mean cumulative score of 0.81 (table 2).
Sensitivity and specificity of serum antibodies against
P aeruginosa compared with P aeruginosa status
defined retrospectively
To calculate sensitivity and specificity from the above data it
was necessary to categorise intermittently infected patients
as either negative or as positive. Since P aeruginosa had been
detected at least once, they were all defined as positive. Thus,
two groups of patients were defined: 68 patients who were
free of P aeruginosa and 115 patients in whom P aeruginosa had
been detected within the previous 2 years.
Overall, specificity was satisfactory (AP 98.5, E 100, EA
95.6) but sensitivity partially was very low (AP 63.5, E 53.0,
EA 73.0). The results for sensitivity were better if only
patients with sputum cultures were considered (AP 76.9, E
67.7, EA 78.5) and were worse if only patients with swabs
were considered (AP 48.0, E 34.0, EA 66.0). The results for
specificity were excellent if only patients with sputum
cultures were considered (AP 100, E 100, EA 100) and were
only slightly worse if only patients with swabs were
considered (AP 98.2, E 100, EA 94.7).
The combination of antibody results by counting exclu-
sively multiple positive results as positive (AP+E, AP+EA,
E+EA, AP+E+EA) generated unsatisfactory results for sensi-
tivity (41.7–52.2%) but good results for specificity (98.6–
100%). The combination of antibody results by assessing a
patient as positive with one of two results positive (AP/E, AP/
EA, E/EA) generated somewhat better results for sensitivity
(70.4–84.3%) but worse results for specificity (90.3–97.2%).
A combination of all three antibodies (AP/E/EA, cumula-
tive antibody score) yielded the best results. Patients were
counted as positive if any of the three antibodies was positive
and negative if no positive antibody result was obtained
(table 3).
Prognostic value of antibody results
Of the 183 patients, a cohort of 162 patients was studied at
three monthly intervals for microbiological status over a
period of 2 years following first antibody determination. This
Table 2 Anti-P aeruginosa antibodies in patients with CF correlated with P aeruginosa status defined retrospectively
Antibodies against
P aeruginosa status according to culture results
Comparison* (p values)
Free (F)
(N = 68)
Intermittent (I)
(N = 27)
Chronic (C)
(N = 88) F v I I v C C v F
Alkaline protease (AP)
Frequency of antibody positive (n/N) 1/68 7/27 66/88 ,0.001 ,0.001 ,0.001
Elastase (E)
Frequency of antibody positive (n/N) 0/68 4/27 57/88 ,0.001 ,0.001 ,0.001
Exotoxin A (EA)
Frequency of antibody positive (n/N) 3/68 11/27 73/88 ,0.001 ,0.001 ,0.001
Cumulative score (AP/E/EA)
Frequency of antibody score >1 (n/N) 3/68 13/27 86/88 ,0.001 ,0.001 ,0.001
Antibody titres were scored as 0 (titre negative ,1:500) and 1 (titre positive .1:500).
*Mann-Whitney test for comparison of antibody levels and Fisher’s exact test for comparison of frequency of patients with antibody score >1, corrected for
multiple comparisons by Bonferroni method.
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allowed the prognostic values of the antibody determinations
to be calculated separately for patients free of P aeruginosa and
for those with intermittent P aeruginosa colonisation. Of 63
patients free of P aeruginosa and with negative antibody results,
14 patients became intermittently infected during the
following 2 years and 49 patients remained free of P
aeruginosa. Of three patients free of P aeruginosa but with
positive antibody results, one patient changed to intermittent
infection and two patients remained free of P aeruginosa. In
the intermittently infected group of 24 patients, 12 patients
had no antibodies. Microbiological follow up was negative in
nine of them and positive in three. Of the other 12 patients
with positive serum antibodies, two became free of P
aeruginosa within the following 2 years and 10 remained
intermittently infected.
The prognostic PPV was therefore low in patients free of P
aeruginosa (33.3%) and high in intermittently infected
patients (83%). The prognostic NPV was high in patients
free of P aeruginosa (77.8%) and 58% in patients with
intermittent infection (table 4).
DISCUSSION
The first part of our study indicated a close correlation
between the microbiologically defined status of P aeruginosa
and serum antibodies against this organism in patients with
CF, as high values for sensitivity and specificity of serum
antibodies were obtained. This confirms similar observations
described by others.13–19 However, the clinical relevance of a
test can best be derived from the positive and negative
predictive values which, in our case, showed that a positive
antibody result indicated the presence of P aeruginosa in the
airways of a CF patient with .93% probability. For patients
with CF chronically infected with P aeruginosa and positive
antibody test results, routine follow up antibody determina-
tions are therefore of no use. On the other hand, a negative
antibody result made the presence of P aeruginosa unlikely
(80%).
In the second part of our study we tested the prognostic
predictive values of antibody determinations, assessing the
time period 2 years after initial antibody determination.
Unexpectedly, the prognostic PPV was low for patients who
were not infected with P aeruginosa (table 4). Although the
number of patients in this study is too small for this value to
have any significance, we have tried to explain this surprising
finding. Of three patients with positive antibody results
despite negative retrospective microbiology, only one patient
became microbiologically positive during the following
2 years but the other two remained P aeruginosa free. This
finding was not consistent with the very high PPV calculated
from the first observation period. Detailed analysis of the two
patients with the unexpected positive antibody titres pro-
vided possible clues: one patient had been colonised with P
aeruginosa 5 years before our study for 18 months and the
bacteria were successfully eradicated. The other patient was
put on inhaled antipseudomonal therapy using tobramycin
for 4 years before our study because of initial clinical
instability without any microbiologically detected P aerugi-
nosa. His subsequent clinical improvement might reflect
successful eradication of P aeruginosa, which had been present
in the lungs and had escaped microbiological detection.
The prognostic NPV in the group free of P aeruginosa was
78%, suggesting that, in patients with negative antibody
results, the probability of P aeruginosa being detected within
the next 2 years was around 20% (10% per year). This value is
in the order of the annual rate of new infections of about 10%
per year.22 The prognostic NPV of the test was therefore
excellent.
The prognostic predictive values calculated for the group of
intermittently infected patients can be applied to patients in
whom P aeruginosa is detected for the first time in swab or
sputum culture. If the serum antibodies were positive, it was
very likely (83%) that the patient maintained the P aeruginosa
infection; if the serum antibodies were negative, the chance
of elimination of P aeruginosa was 58% (table 4).
The microbiological status of a patient in our study was
retrospectively defined by sputum samples or oropharyngeal
swabs taken regularly every 3 months. According to this, we
cannot differentiate between colonisation and infection since
we believe these two conditions to be a continuum in patients
with CF. Although this widespread regimen is feasible in
everyday patient care and approximates the recommenda-
tions for surveillance of CF patients,23 the results of swab
analyses may be erroneous24 and the impact of swab results
in previous studies lead to controversial conclusions, yielding
either a high PPV25 or a high NPV.26 27 Partly relying on swab
culture results may thus introduce some inaccuracy into the
interpretation of our serological data. We therefore consid-
ered sputum or swab culture results separately. For patients
in whom sputum cultures were available, the PPV of the
cumulative antibody test results was 100%, meaning that a
CF patient with positive results in any antibody determination
Table 3 Sensitivity and specificity of cumulative anti-P aeruginosa antibody scores
according to the method by which material was obtained for microbiological culture
Sputum only All (sputum + swab) Swab only
Number of subjects (n) 76 183 107
Sensitivity % (95% CI) 95.4 (87.1 to 99.0) 86.1 (78.4 to 91.8) 74.0 (59.7 to 85.4)
(n/N) 62/65 99/115 37/50
Specificity % (95% CI) 100 (71.5 to 100) 95.6 (87.6 to 99.1) 94.7 (85.4 to 98.9)
(n/N) 11/11 65/68 54/57
PPV % (95% CI) 100 (94.2 to 100) 97.1 (91.6 to 99.4) 92.5 (79.6 to 98.4)
NPV % (95% CI) 78.6 (49.2 to 95.3) 80.2 (69.9 to 88.3) 80.6 (69.1 to 89.2)
PPV, positive predictive value; NPV, negative predictive value.
Predictive values were calculated for the given prevalence—that is, 61.5% for all patients (115/183), 85.5% for
patients with sputum cultures (65/76), and 45.0% for patients with swabs (50/107).
Table 4 Prognostic values of serum antibody
determination: results from evaluation over the 2 years
following the initial determination of antibody titres
Free (N = 66) Intermittent (N = 24)
PPV % (95% CI) 33.3 (0.8 to 90.6) 83.0 (51.6 to 97.9)
n/N 1/3 10/12
NPV % (95% CI) 77.8 (76.5 to 94.4) 58.0 (27.7 to 84.8)
n/N 49/63 7/12
PPV, positive predictive value; NPV, negative predictive value.
Predictive values were calculated on the basis of the prevalence of P
aeruginosa after 2 years based on the serum antibody results (15/66
(22.7%) in the P aeruginosa free group and 13/24 (54.2%) in the
intermittently infected group) to determine the probability for a CF patient
to shift his or her P aeruginosa status depending on the antibody titre.
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actually has been colonised with P aeruginosa within the
previous 2 years. As sputum is considered the reference
method, the same conclusion must be drawn for patients in
whom only oropharyngeal swabs were available. This means
that, independent of the method by which material for
microbiological testing was obtained, a positive cumulative
serum antibody result indicates P aeruginosa colonisation within
the previous 2 years.
Interestingly, the NPV of the cumulative antibody results
of around 80% did not change if sputum or swab culture
results were calculated independently, indicating that nega-
tive results of antibody determination did not rule out future
colonisation with P aeruginosa.
Our calculations of PPV and NPV depend on the prevalence
of P aeruginosa and thereby on successful early therapeutic
intervention strategies and on the age distribution of our
cohort, so our conclusions may not be applicable to other
populations of CF patients. Overall, the prevalence of P
aeruginosa in our patients (61.5%) was high and comparable
to published data.28 Among adult patients the rate of chronic
P aeruginosa colonisation was 67%, which is comparable to
data from adult CF centres showing a chronic P aeruginosa
infection rate of about 70%.22 The rate of P aeruginosa
detection in children under the age of 6 years was 18% in
our group, which is lower than the 30% reported elsewhere.29
As the predictive values depend on the prevalence of P
aeruginosa, approximate adjustments need to be made for
individual patients. In younger patients the prevalence of P
aeruginosa is lower, leading to a worsening of the PPV but to
an improvement in the NPV. Using our results for the
sensitivity (86%) and specificity (90%) of the test, the NPV is
only 80% for the P aeruginosa prevalence of 61% in our study
group compared with 96% for the prevalence of 18% found in
children less than 6 years of age. This means that negative
serum antibodies against P aeruginosa make an infection with
this organism less likely, the younger the child is.
The determination of a collection of three serum antibodies
against P aeruginosa (AP, E, and EA) in patients with CF is
reliable if cumulative antibody scores are used. Positive
antibody results almost prove colonisation with P aeruginosa,
while negative test results indicate the absence of P aeruginosa
with increasing probability as age decreases. We conclude
that, from a clinical perspective, regular determination of
serum antibodies against P aeruginosa may be useful in
patients with negative microbiological P aeruginosa status. If
antibody titres rise under these conditions, there is a high
suspicion for possible infection with P aeruginosa and we
suggest using eradication treatment, even in the absence of
microbiological detection of P aeruginosa. At present our regime
for eradication of P aeruginosa relies solely on the microbiological
detection of the organism. In future, early initiation and
possibly the intensity and duration of antipseudomonal
treatment may be determined by antibody test results, but
more longitudinal data will be necessary to achieve this.
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